Kabi Is Ready To Get More Aggressive On US Market Share
With supply shortages easing and a period of channel destocking largely over, Fresenius Kabi’s US injectables business is preparing to fight hard to maintain its market position, group CEO Stephan Sturm says.
You may also be interested in...
Helping to alleviate shortages of critical US injectables, including controlled substances, has strengthened Hikma’s relationships with its hospital customers in the US, including with Civica Rx, CEO Siggi Olafsson told Generics Bulletin.
As a late entrant to the European adalimumab market, Fresenius is cooling expectations for sales of its Idacio biosimilar while it continues work on late-stage candidates pegfilgrastim and tocilizumab.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.